G1 Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference on January 13, 2021
G1 Therapeutics, a clinical-stage oncology company, announced that CEO Jack Bailey will present a company update at the 39th Annual J.P.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
G1 Therapeutics, a clinical-stage oncology company, announced that CEO Jack Bailey will present a company update at the 39th Annual J.P. Morgan Healthcare Conference on January 13, 2021, at 2:50 p.m. ET. The presentation will be accessible via a live and archived webcast on the company’s events page. G1 Therapeutics focuses on developing therapies to improve cancer treatment outcomes, including Trilaciclib, which is under FDA review with a PDUFA action date of February 15, 2021, and Rintodestrant, aimed at treating ER+ breast cancer.
Details
News Market Reaction – GTHX
The recorded move for GTHX in the trading session of this news was -1.60%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
RESEARCH TRIANGLE PARK, N.C., Jan. 05, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that Chief Executive Officer Jack Bailey will present a company update at the 39th Annual J.P. Morgan Healthcare Conference on January 13, 2021 at 2:50 p.m. ET.
To access the live and archived webcast of the presentation, please visit the Events & Presentations page of the G1 website.
About G1 Therapeutics
G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and delivery of next generation therapies that improve the lives of those affected by cancer. The company is developing and advancing two novel therapies. Trilaciclib is a first-in-class therapy designed to improve outcomes for patients being treated with chemotherapy. Trilaciclib received Breakthrough Therapy Designation and is under review by the U.S. Food and Drug Administration (FDA) with a PDUFA action date of February 15, 2021. Rintodestrant is a potential best-in-class oral selective estrogen receptor degrader (SERD) for the treatment of ER+ breast cancer.
G1 Therapeutics is based in Research Triangle Park, N.C. For additional information, please visit www.g1therapeutics.com and follow us on Twitter @G1Therapeutics.
Contact:
Will Roberts
G1 Therapeutics, Inc.
Vice President, Investor Relations & Corporate Communications
610-304-5882
wroberts@g1therapeutics.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.